calcium: 3.06\m=+-\0.08vs 2.50\m=+-\0.02(normal males) (p<0.01) and 2.43\m=+-\0.02mmol/l (osteoporosis) (p<0.01): osteocalcin: 1.10\m=+-\0.08vs 0.56\m=+-\0.16(normal males) (p<0.05) and 0.53\m=+-\0.21nmol/l (osteoporosis) (p<0.05). Following treatment with alfacalcidol, no significant change was observed in PTH, calcium or osteocalcin serum concentrations in any group. These results show that maximal conversion of alfacalcidol to calcitriol occurs within a few hours of administration of alfacalcidol in normal males and patients with primary hyperparathyroidism and osteoporosis. Whilst this may reflect differences in activity of the enzyme 2 5-hydroxylase among these groups, other explanations, such as differences in calcitriol clearance, cannot be excluded.
SJ Gallacher, University Department of Medicine, Queen Elizabeth Building, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK In recent years calcitriol has been recognized increas¬ ingly as a key hormone in the control of PTH secretion (1) . Conversely, PTH is also of major importance in the metabolism of calcitriol, with one of its principal actions being stimulation of the 1 a-hydroxylase enzyme, which leads to increased conversion of calcidiol to the active metabolite of vitamin D3, calcitriol (2) . 
Results
In each group, calcitriol levels rose to a peak 2-3 h after administration of alfacalcidol (Fig. 1) 
